Astellas' Zolbetuximab Is a Promising Therapy for HER2-Negative Gastric Cancer

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab.